Skip to main content

Table 1 The characteristics of included studies

From: PD-1 inhibitors versus chemotherapy as second-line treatment for advanced esophageal squamous cell carcinoma: a meta-analysis

Study

Phase

Treatment line

Arm

Patients

PD-L1+ patients

Age, median (range)

Male (%)

ECOG (%)

Intervention

0–1

2

Kojima 2020 [15] KEYNOTE-181

III

2

PD-1 inhibitor

198

85

NA

NA

NA

NA

Pembrolizumab 200 mg Q3W

Chemotherapy

203

82

NA

NA

NA

NA

Investigator choice chemotherapy

Kato 2019 [16] ATTRACTION-3

III

2

PD-1 inhibitor

210

101

64 (57, 69)

179 (85%)

210 (100%)

0 (0%)

Nivolumab 240 mg Q2W

Chemotherapy

209

102

67 (57, 72)

185 (89%)

209 (100%)

0 (0%)

Investigator choice chemotherapy

Huang 2020 [17] ESCORT

III

2

PD-1 inhibitor

228

93

60 (54, 65)

208 (91%)

228 (100%)

0 (0%)

Camrelizumab 200 mg Q2W

Chemotherapy

220

98

60 (54, 65)

192 (87%)

220 (100%)

0 (0%)

Investigator choice chemotherapy

Xu 2020 [18] ORIENT-2

II

2

PD-1 inhibitor

95

NA

NA

NA

95 (100%)

0 (0%)

Sintilimab 200 mg Q3W

Chemotherapy

95

NA

NA

NA

95 (100%)

0 (0%)

Investigator choice chemotherapy

Ajani 2021 [19] RATIONALE 302

III

2

PD-1 inhibitor

256

NA

NA

NA

256 (100%)

0 (0%)

Tislelizumab 200 mg Q3W

Chemotherapy

256

NA

NA

NA

256 (100%)

0 (0%)

Investigator choice chemotherapy

  1. Abbreviations: NA not available, ECOG Eastern Cooperative Oncology Group performance status